Sagent FDA Friday, July 10, 2026 0.00 Neutral

FDA Approves ZYOGREEN — Sagent Pharmaceuticals

Sagent Pharmaceuticals announced the FDA approval of Indocyanine Green (NDA 218579), expanding its portfolio of critical diagnostic products for the interstitial route. This market-moving approval strengthens the company’s position in the access catheter and contrast agent sectors, likely enhancing revenue potential in the intravascular diagnostic space.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed